Veracyte Inc Asset Resilience Ratio
Veracyte Inc asset resilience ratio. Veracyte Inc (VCYT) has an Asset Resilience Ratio of 12.49% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Veracyte Inc (VCYT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Veracyte Inc (2012–2025)
Asset resilience ratio of Veracyte Inc from 2012 to 2025. This chart shows how Veracyte Inc's Asset Resilience Ratio has changed over time. Read Veracyte Inc (VCYT) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Veracyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Veracyte Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $185.71 Million | 12.49% |
| Total Liquid Assets | $185.71 Million | 12.49% |
Asset Resilience Insights
- Moderate Liquidity: Veracyte Inc has 12.49% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Veracyte Inc Industry Peers by Asset Resilience Ratio
Compare Veracyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Veracyte Inc Asset Resilience Ratio by Year (2012–2025)
Veracyte Inc asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Veracyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.58% | $50.31 Million | $1.41 Billion | -0.30pp |
| 2024-12-31 | 3.87% | $50.35 Million | $1.30 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $1.11 Billion | -- |
| 2022-12-31 | 2.13% | $24.61 Million | $1.16 Billion | +1.79pp |
| 2021-12-31 | 0.33% | $3.96 Million | $1.19 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $78.67 Million | -- |
| 2016-12-31 | 0.12% | $120.00K | $101.03 Million | -0.04pp |
| 2015-12-31 | 0.16% | $118.00K | $75.28 Million | +0.05pp |
| 2014-12-31 | 0.11% | $70.00K | $64.84 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $79.63 Million | -- |
| 2012-12-31 | 0.26% | $50.00K | $19.07 Million | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more